# A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

> **NCT06672978** · PHASE2 · RECRUITING · sponsor: **Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)** · enrollment: 66 (estimated)

## Conditions studied

- Acute Pyelonephritis
- Complicated Urinary Tract Infection

## Interventions

- **DRUG:** Meropenem-Vaborbactam
- **DRUG:** Antibiotics

## Key facts

- **NCT ID:** NCT06672978
- **Lead sponsor:** Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-03
- **Primary completion:** 2027-01
- **Final completion:** 2027-07
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06672978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06672978, "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06672978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*